Who Paid My Doc
Holly Tolhurst
Clinical Nurse Specialist, Family Health Jacksonville, AR Nurse Practitioner
NPI 1659012425 CMS profile 11352593
1813 T P White Dr, Jacksonville, AR 72076
General payments
$45
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Holly Tolhurst of Jacksonville, AR is reported in the CMS Open Payments database as having received $45 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 15th percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $45 | 1 |
Beside peers
- Holly Tolhurst
- Clinical Nurse Specialist, Family Health median
- Middle half of Clinical Nurse Specialist, Family Health
- National median
In program year 2025, general payments to Holly Tolhurst were reported at $0. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.
Show as a table
| Year | Holly Tolhurst | Clinical Nurse Specialist, Family Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $151 | $46–$400 | $132 |
| 2022 | $0 | $153 | $37–$527 | $149 |
| 2023 | $45 | $139 | $50–$451 | $160 |
| 2024 | $0 | $150 | $46–$571 | $164 |
| 2025 | $0 | $216 | $57–$492 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
336
Drug cost
$2,990
Branded share of claims
44%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Fluticasone Propionate | Generic | 73 | $749 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 51 | $609 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 56 | $452 | |
| Ofloxacin | Generic | 11 | $312 | |
| Ondansetron Odt Ondansetron | Brand | 29 | $303 | |
| Doxycycline Hyclate | Generic | 17 | $133 | |
| Clindamycin Hcl | Generic | 13 | $132 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 12 | $101 | |
| Azithromycin | Generic | 27 | $87 | |
| Amoxicillin | Generic | 12 | $45 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 62 billing codesPaid by Medicare
$33,173
Medicare patients
387
Services billed
1,116
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 50% | |
| Ischemic heart disease | 30% | |
| Diabetes | 28% | |
| Depression | 28% | |
| Chronic kidney disease | 20% | |
| COPD | 20% | |
| Atrial fibrillation | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 13 | 46 | $29 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 13 | 58 | $4 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 | Office | 11 | 11 | $1 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Nurse Specialist, Family Health in Arkansas
Linda Dukes
Clinical Nurse Specialist, Family Health · Hot Springs, AR
Michelle Auld
Clinical Nurse Specialist, Family Health · Hot Springs, AR
Jennifer Jones
Clinical Nurse Specialist, Family Health · Hot Springs, AR
Sherry McCrary
Clinical Nurse Specialist, Family Health · Wynne, AR
Madison Birdno
Clinical Nurse Specialist, Family Health · Jonesboro, AR
Marie Pham-Russell
Clinical Nurse Specialist, Family Health · Fort Smith, AR
Related records
Clinical Nurse Specialist, Family Health in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Nurse Specialist, Family Health
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.